menu
    • menu

    Find Abemaciclib manufacturers, exporters & distributors on PharmaCompass

    Porton Abemaciclib

    Virtual Booth

    Contact Supplier

    Egis Abemaciclib

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Shandong Loncom Pharmaceutical Abemaciclib

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    20

    API Suppliers

    API Suppliers

    3

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    1

    EU WC

    EU WC

    0

    KDMF

    KDMF

    4

    NDC API

    NDC API

    0

    VMF

    NDC API

    17

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 24,387

    MARKET PLACE

    2

    API

    0

    FDF

    14INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    32

    FDF Dossiers

    FDF Dossiers

    8

    FDA Orange Book

    FDA (Orange Book)

    6

    Europe

    Europe

    4

    Canada

    Canada

    6

    Australia

    Australia

    4

    South Africa

    South Africa

    4

    Listed Dossiers

    Listed Dossiers

    28DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    17

    US Patents

    8

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    2

    Data Compilation #PharmaFlow

    2

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    76

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    474,171,738

    Annual Reports

    9,189

    Finished Drug Prices

    Listed Dossiers

    123 RELATED EXCIPIENT COMPANIES

    193EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 1231929-97-7, Ly2835219, Verzenio, Ly2835219 free base, Ly-2835219, Unii-60uab198hk
    Molecular Formula
    C27H32F2N8
    Molecular Weight
    506.6  g/mol
    InChI Key
    UZWDCWONPYILKI-UHFFFAOYSA-N
    FDA UNII
    60UAB198HK
    Abemaciclib
    Abemaciclib is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.
    Abemaciclib is a Kinase Inhibitor. The mechanism of action of abemaciclib is as a Kinase Inhibitor.
    1 2D Structure

    Abemaciclib

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
    2.1.2 InChI
    InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)
    2.1.3 InChI Key
    UZWDCWONPYILKI-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F
    2.2 Other Identifiers
    2.2.1 UNII
    60UAB198HK
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3h-benzimidazol-5-yl)pyrimidin-2-yl)amine

    2. 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3h-benzoimidazol-5-yl)pyrimidin-2-yl)amine

    3. Abemaciclib Mesylate

    4. Ly-2835219

    5. Ly2385219

    6. Ly2835210

    7. Ly2835219

    8. Verzenio

    2.3.2 Depositor-Supplied Synonyms

    1. 1231929-97-7

    2. Ly2835219

    3. Verzenio

    4. Ly2835219 Free Base

    5. Ly-2835219

    6. Unii-60uab198hk

    7. N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1h-benzo[d]imidazol-6-yl)pyrimidin-2-amine

    8. N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine

    9. Abemaciclib (ly2835219)

    10. 60uab198hk

    11. Ly 2835219

    12. Hy-16297a

    13. Cs-1230

    14. 2-pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1h-benzimidazol-6-yl)

    15. N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-1,3-benzodiazol-5-yl)pyrimidin-2-amine

    16. N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-amine

    17. Ly2835219 (free Base)

    18. Abemaciclib [usan:inn]

    19. Abemaciclib,ly2835219

    20. Verzenios

    21. Rimidin-2-amine

    22. Verzenio (tn)

    23. 6zv

    24. N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1h-benzimidazol-6-yl]py Rimidin-2-amine

    25. Cdk4/6 Dual Inhibitor

    26. Ly2835210

    27. Abemaciclib [mi]

    28. Abemaciclib [inn]

    29. Abemaciclib [jan]

    30. Abemaciclib (jan/usan)

    31. Abemaciclib [usan]

    32. Abemaciclib [who-dd]

    33. Gtpl7382

    34. Schembl2487229

    35. Chembl3301610

    36. Abemaciclib [orange Book]

    37. Dtxsid20673119

    38. Ex-a521

    39. Ly 2835219 (free Base)

    40. Hms3673i05

    41. Bcp13079

    42. Ex-a1588

    43. Bdbm50110183

    44. Mfcd22665744

    45. Nsc768073

    46. Nsc783671

    47. S5716

    48. Zinc72318121

    49. 1231929-97-7, Verzenio,

    50. Akos025404907

    51. Ly2835219 Free Base (abemaciclib)

    52. Ccg-269750

    53. Db12001

    54. Nsc-768073

    55. Nsc-783671

    56. Sb16476

    57. Ncgc00351599-02

    58. Ncgc00351599-06

    59. 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3h-benzimidazol-5-yl)pyrimidin-2-yl)amine

    60. 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3h-benzoimidazol-5-yl)pyrimidin-2-yl)amine

    61. Ac-30666

    62. As-10230

    63. Da-33422

    64. Ly2835219 Ms Salt, Abemaciclib Ms Salt

    65. Ft-0700134

    66. Ly 2835210

    67. A12989

    68. D10688

    69. J-690083

    70. Q23901483

    71. [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3h-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine

    72. 2-pyrimidinamine, N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1h-benzimidazol-6-yl]-

    73. 2-pyrimidinamine,n-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1h-benzimidazol-6-yl]-

    74. N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1h-benzimidazol-6-yl]py

    2.4 Create Date
    2010-07-06
    3 Chemical and Physical Properties
    Molecular Weight 506.6 g/mol
    Molecular Formula C27H32F2N8
    XLogP33.8
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count9
    Rotatable Bond Count7
    Exact Mass506.27179938 g/mol
    Monoisotopic Mass506.27179938 g/mol
    Topological Polar Surface Area75 Ų
    Heavy Atom Count37
    Formal Charge0
    Complexity723
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 1  
    Drug NameVERZENIO
    Active IngredientABEMACICLIB
    CompanyELI LILLY AND CO (Application Number: N208716. Patent: 7855211)

    4.2 Drug Indication

    * Indicated in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. * Inidicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.

    Early Breast Cancer

    Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence (see section 5. 1).

    In pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.

    Advanced or Metastatic Breast Cancer

    Verzenios is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.

    In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist.

    Treatment of Ewing sarcoma

    Treatment of breast cancer

    Treatment of high-grade glioma, Treatment of neuroblastoma

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    In combination with fulvestrant, the progression-free survival for patients with HR-positive, HER2-negative breast cancer was 16.4 months compared to 9.3 months for patients taking a placebo with fulvestrant. As a monotherapy, 19.7% of patients taking abemaciclib achieved complete or partial shrinkage of their tumors for a median 8.6 months after treatment. Abemaciclib induces cell cycle arrest and exerts an antitumor activity in human tumor xenograft models. In patient investigations and a healthy volunteer study, abemaciclib is not shown to induce any clinically significant changes in the QTc interval.

    5.2 FDA Pharmacological Classification
    5.2.1 Active Moiety
    ABEMACICLIB
    5.2.2 FDA UNII
    60UAB198HK
    5.2.3 Pharmacological Classes
    Kinase Inhibitors [MoA]; Kinase Inhibitor [EPC]
    5.3 ATC Code

    L01EF03

    L - Antineoplastic and immunomodulating agents

    L01 - Antineoplastic agents

    L01E - Protein kinase inhibitors

    L01EF - Cyclin-dependent kinase (cdk) inhibitors

    L01EF03 - Abemaciclib

    5.4 Absorption, Distribution and Excretion

    Absorption

    The plasma concentration of the drug increases in a dose-proportional manner. Following a single oral dose administration of 200 mg abemaciclib, the mean peak plasma concentration (Cmax) of 158 ng/mL is reached after 6 hours. The median time to reach maximum plasma concentration (Tmax) ranges from 4-6 hours following an oral administration of abemaciclib over a range of 50275 mg, but may range up to 24 hours. The absolute bioavailability of the drug is reported to be 45%.

    Route of Elimination

    Following a single oral dose of 150mg radiolabeled abemaciclib, approximately 81% of the total dose was recovered in feces while 3% of the dose was detected in urine. The majority of the drug is exceted as metabolites.

    Volume of Distribution

    The geometric mean systemic volume of distribution is approximately 690.3 L (49% CV).

    Clearance

    The geometric mean hepatic clearance (CL) of abemaciclib in patients was 26.0 L/h (51% CV).

    5.5 Metabolism/Metabolites

    Abemaciclib mainly undergoes hepatic metabolism mediated by CYP3A4. The major metabolite formed is N-desethylabemaciclib (M2), while other metabolites hydroxyabemaciclib (M20), hydroxy-N-desethylabemaciclib (M18), and an oxidative metabolite (M1) are also formed. M2, M18, and M20 are equipotent to abemaciclib and their AUCs accounted for 25%, 13%, and 26% of the total circulating analytes in plasma, respectively.

    5.6 Biological Half-Life

    The mean plasma elimination half-life for abemaciclib in patients was 18.3 hours (72% CV).

    5.7 Mechanism of Action

    Regulation of cell cycle is crucial in maintaining proper cell growth; dysregulated cell cycle signalling pathway is a key component in inducing hyperproliferation of cells and tumor formation in various cancers. G1 to S phase cell cycle progression, or transition through the G1 restriction point (R), is promoted by the retinoblastoma tumor suppressor protein (Rb)-mediated pathway. Activation of Rb-mediated pathway requires the interaction of Cyclin-dependent kinases (CDK) 4 and 6 with D-type cyclins, which drives the formation of active CDK4/CDK6 and subsequent phosphorylation of Rb. Rb is a tumor suppressant protein that inhibits proliferation through binding to and suppressing the activity of the E2F family of transcription factors. However, phosphorylation of Rb relieves suppression of E2F to allow expression of genes required for passage through the restriction point. This leads to increased expression of downstream signalling molecules and activity of protein kinases that promote the cell cycle progression and initiation of DNA replication. Phosphorylation of Rb and other proteins by CDK4/6 additionally leads to transcription of genes involved in cell cycle-independent activities including signal transduction, DNA repair transcriptional control, and mRNA processing. Abemaciclib selectively inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in a G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells. Unlike other CDK inhibitors such as [DB09073] and [DB11730], abemaciclib exhibits greater selectivity for CDK4 compared to CDK6.

    API SUPPLIERS

    read-more
    read-more

    01

    Porton Pharma Solutions

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothPorton Pharma Solutions: Value creation via innovation & discovery through technical platforms.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Porton Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Shandong Loncom Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothShandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Shandong Loncom Pharmaceutical company banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Egis Pharmaceuticals PLC

    Hungary

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI India 2024
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Contact Supplier Contact Supplier
    Flag Hungary
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Egis Pharmaceuticals

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Polpharma

    Poland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothPolpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Contact Supplier Contact Supplier
    Flag Poland
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Polpharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Seqens

    France

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSeqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Seqens Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Shandong Boyuan Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothShandong Boyuan is a Chinese manufacturer of GMP & CEP APIs & pharmaceutical intermediates.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Shandong Boyuan Pharmaceutical

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Sichuan Elixir Pharmaceuticals

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Sichuan Elixir Pharmaceuticals

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    MSN Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    SupplySide West 2024
    Not Confirmed
    arrow

    MSN Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 34714

    Submission : 2020-03-31

    Status : Active

    Type : II

     CEP/COS JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2022-09-02

    Valid Till : 2025-05-05

    Written Confirmation Number : WC-0349

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 54893-0098

    Start Marketing Date : 2020-03-30

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    MSN Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    SupplySide West 2024
    Not Confirmed
    arrow

    MSN Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40612

    Submission : 2024-09-30

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 54893-0098

    Start Marketing Date : 2020-03-30

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Shandong Anhong Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    SupplySide West 2024
    Not Confirmed
    arrow

    Shandong Anhong Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2024-09-23

    Pay. Date : 2024-08-27

    DMF Number : 40315

    Submission : 2024-08-30

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    USDMF

    read-more
    read-more

    01

    World Vaccine Congress
    Not Confirmed

    01

    Msn Laboratories Private Ltd

    India
    arrow
    World Vaccine Congress
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40612

    Submission : 2024-09-30

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    World Vaccine Congress
    Not Confirmed

    02

    Msn Laboratories Private Ltd

    India
    arrow
    World Vaccine Congress
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 34714

    Submission : 2020-03-31

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    World Vaccine Congress
    Not Confirmed

    03

    Shandong Anhong Pharmaceutical Co Lt...

    China
    arrow
    World Vaccine Congress
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2024-09-23

    Pay. Date : 2024-08-27

    DMF Number : 40315

    Submission : 2024-08-30

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    EU WC

    read-more
    read-more

    01

    MSN Laboratories

    India
    SupplySide West 2024
    Not Confirmed
    arrow

    MSN Laboratories

    India
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Abemaciclib IH

    Date of Issue : 2022-09-02

    Valid Till : 2025-05-05

    Written Confirmation Number : WC-0349

    Address of the Firm : MIs. MSN Laboratories Private Limited, Unit-II, sv. No, 50, Kardanur (Village), ...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662921000,"product":"ABEMACICLIB ABE3 (QY)","address":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PVT LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"ARTIN ROSE LIMITED SIRKETI","customerCountry":"TURKEY","quantity":"0.02","actualQuantity":"20","unit":"GMS","unitRateFc":"36.2","totalValueFC":"711.2","currency":"USD","unitRateINR":2850,"date":"12-Sep-2022","totalValueINR":"57000","totalValueInUsd":"711.2","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"4123414","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1711996200,"product":"ABEMACICLIB","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"AMMAN","customer":"HIKMA PHARMACEUTICALS","customerCountry":"JORDAN","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"25000","totalValueFC":"12193.4","currency":"USD","unitRateINR":2036478,"date":"02-Apr-2024","totalValueINR":"1018239","totalValueInUsd":"12193.4","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"8837718","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"JORDAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1720204200,"product":"ABEMACICLIB","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"STOCKHOLM","customer":"XSPRAY PHARMA","customerCountry":"SWEDEN","quantity":"0.02","actualQuantity":"0.02","unit":"KGS","unitRateFc":"50000","totalValueFC":"977.2","currency":"USD","unitRateINR":4084100,"date":"06-Jul-2024","totalValueINR":"81682","totalValueInUsd":"977.2","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"2223799","productDescription":"API","marketType":"REGULATED MARKET","country":"SWEDEN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""}]
    12-Sep-2022
    06-Jul-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Granulation

    read-more
    read-more

    Topical

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    STOCK RECAP #PipelineProspector

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search